Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy and Safety of AJU-S56 5% in Dry Eye Syndrome Patients
Sponsor: AJU Pharm Co., Ltd.
Summary
This study is planned to Evaluate the Efficacy and Safety of test drug (AJU-S56 5%) compared to control drug(vehicle) in Patients with Dry Eye Disease.
Official title: The Purpose of This Clinical Study is to Prove That the Test Drug (AJU-S56 5%) is Superior to the Control Drug After 24 Weeks of Administration to Patients Who Have Moderate or Severe Dry Eye Syndrome
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
INTERVENTIONAL
Enrollment
396
Start Date
2023-11-10
Completion Date
2024-05
Last Updated
2024-04-08
Healthy Volunteers
No
Conditions
Interventions
AJU-S56 5%
After Randomization(Week 0), Participants will be administered with the durg, QID(4 times in a day, and 1 drop per each times) until end of trial(Week 24).
Placebo Group(Vehicle)
After Randomization(Week 0), Participants will be administered with the durg, QID(4 times in a day, and 1 drop per each times) until end of trial(Week 24).
Locations (1)
AJU Pharm Co., Ltd.
Seoul, South Korea